{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:15:21Z","timestamp":1791976521458,"version":"4.4.0"},"reference-count":41,"publisher":"The Endocrine Society","issue":"2","license":[{"start":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T00:00:00Z","timestamp":1536796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Safety concerns have been raised regarding premature mortality, diabetes, neoplasia, and cerebrovascular disease in association with GH therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To assess incidence of key safety outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Prospective, multinational, observational study (1999 to 2015).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>A total of 22,311 GH-treated children from 827 investigative sites in 30 countries.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients<\/jats:title>\n                  <jats:p>Children with growth disorders.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Interventions<\/jats:title>\n                  <jats:p>GH treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main outcome measures<\/jats:title>\n                  <jats:p>Standardized mortality ratio (SMR) and standardized incidence ratio (SIR) with 95% CIs for mortality, diabetes, and primary cancer using general population registries.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Predominant short stature diagnoses were GH deficiency (63%), idiopathic short stature (13%), and Turner syndrome (8%), with mean \u00b1 SD follow-up of 4.2 \u00b1 3.2 years (\u223c92,000 person-years [PY]). Forty-two deaths occurred in patients with follow-up, with an SMR (95% CI) of 0.61 (0.44, 0.82); the SMR was elevated for patients with cancer-related organic GH deficiency [5.87 (3.21, 9.85)]. Based on 18 cases, type 2 diabetes mellitus (T2DM) risk was elevated [SIR: 3.77 (2.24, 5.96)], but 72% had risk factors. In patients without cancer history, 14 primary cancers were observed [SIR: 0.71 (0.39, 1.20)]. Second neoplasms occurred in 31 of 622 cancer survivors [5.0%; 10.7 (7.5, 15.2) cases\/1000 PY] and intracranial tumor recurrences in 67 of 823 tumor survivors [8.1%; 16.9 (13.3, 21.5) cases\/1000 PY]. All three hemorrhagic stroke cases had risk factors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>GeNeSIS (Genetics and Neuroendocrinology of Short Stature International Study) data support the favorable safety profile of pediatric GH treatment. Overall risk of death or primary cancer was not elevated in GH-treated children, and no hemorrhagic strokes occurred in patients without risk factors. T2DM incidence was elevated compared with the general population, but most cases had diabetes risk factors.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jc.2018-01189","type":"journal-article","created":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T18:29:36Z","timestamp":1536863376000},"page":"379-389","source":"Crossref","is-referenced-by-count":73,"title":["Safety Outcomes During Pediatric GH Therapy: Final Results From the Prospective GeNeSIS Observational Program"],"prefix":"10.1210","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6195-2780","authenticated-orcid":false,"given":"Christopher J","family":"Child","sequence":"first","affiliation":[{"name":"Eli Lilly and Company, Windlesham, Surrey, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan G","family":"Zimmermann","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George P","family":"Chrousos","sequence":"additional","affiliation":[{"name":"National and Kapodistrian University of Athens, School of Medicine, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Cummings","sequence":"additional","affiliation":[{"name":"Dalhousie University\/IWK Health Centre, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheri L","family":"Deal","sequence":"additional","affiliation":[{"name":"University of Montreal and CHU Ste-Justine, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonobu","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Jia","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lawrence","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of Eastern Ontario, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Linglart","sequence":"additional","affiliation":[{"name":"H\u00f4pital Bic\u00eatre Paris Sud, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Loche","sequence":"additional","affiliation":[{"name":"Ospedale Pediatrico Microcitemico \u201cA. Cao,\u201d AO Brotzu, Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Maghnie","sequence":"additional","affiliation":[{"name":"Istituto Giannina Gaslini, University of Genova, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobo","family":"P\u00e9rez S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Corporaci\u00f3 Sanit\u00e0ria Parc Taul\u00ed, Sabadell, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Polak","sequence":"additional","affiliation":[{"name":"H\u00f4pital Universitaire Necker Enfants Malades and Universit\u00e9 Paris Descartes, Centre des Maladies Endocrines Rares de la Croissance, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Predieri","sequence":"additional","affiliation":[{"name":"University of Modena and Reggio Emilia, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Richter-Unruh","sequence":"additional","affiliation":[{"name":"University Children\u2019s Hospital, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron G","family":"Rosenfeld","sequence":"additional","affiliation":[{"name":"Oregon Health and Science University, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Yeste","sequence":"additional","affiliation":[{"name":"Hospital Vall d\u2019Hebron, Universidad Aut\u00f3noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Yorifuji","sequence":"additional","affiliation":[{"name":"Osaka City General Hospital, Miyakojima-ku, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner F","family":"Blum","sequence":"additional","affiliation":[{"name":"University of Giessen, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2018,9,13]]},"reference":[{"issue":"6","key":"2020071622483907800_B1","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1054\/ghir.2000.0175","article-title":"Safety issues in children and adolescents during growth hormone therapy: a review","volume":"10","author":"Clayton","year":"2000","journal-title":"Growth Horm IGF Res"},{"issue":"1","key":"2020071622483907800_B2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1210\/jc.2009-0178","article-title":"Long-term safety of recombinant human growth hormone in children","volume":"95","author":"Bell","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2020071622483907800_B3","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1530\/EJE-15-0873","article-title":"GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults","volume":"174","author":"Allen","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"8595","key":"2020071622483907800_B4","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(88)91968-X","article-title":"Leukaemia in patients treated with growth hormone","volume":"331","author":"Watanabe","year":"1988","journal-title":"Lancet"},{"issue":"1","key":"2020071622483907800_B5","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/S0022-3476(97)70008-8","article-title":"Risk of leukemia in children treated with human growth hormone: review and reanalysis","volume":"131","author":"Allen","year":"1997","journal-title":"J Pediatr"},{"issue":"7","key":"2020071622483907800_B6","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1210\/jcem.87.7.8606","article-title":"Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study","volume":"87","author":"Sklar","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2020071622483907800_B7","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1210\/jc.2006-0656","article-title":"Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor","volume":"91","author":"Ergun-Longmire","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2020071622483907800_B8","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1210\/jc.2015-1002","article-title":"Risk of neoplasia in pediatric patients receiving growth hormone therapy: a report from the Pediatric Endocrine Society Drugs and Therapeutics Committee","volume":"100","author":"Raman","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"9204","key":"2020071622483907800_B9","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S0140-6736(99)04055-6","article-title":"Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment","volume":"355","author":"Cutfield","year":"2000","journal-title":"Lancet"},{"issue":"2","key":"2020071622483907800_B10","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1210\/jc.2011-1995","article-title":"Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study","volume":"97","author":"Carel","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2020071622483907800_B11","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1212\/WNL.0000000000000737","article-title":"Growth hormone treatment for childhood short stature and risk of stroke in early adulthood","volume":"83","author":"Poidvin","year":"2014","journal-title":"Neurology"},{"issue":"3","key":"2020071622483907800_B12","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000444124","article-title":"Assessment of primary cancer incidence in growth hormone-treated children: comparison of a multinational, prospective observational study with population databases","volume":"85","author":"Child","year":"2016","journal-title":"Horm Res Paediatr"},{"issue":"9","key":"2020071622483907800_B13","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1210\/jc.2017-00214","article-title":"Mortality in children receiving growth hormone treatment of growth disorders: data from the Genetics and Neuroendocrinology of Short Stature International Study","volume":"102","author":"Quigley","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2020071622483907800_B14","doi-asserted-by":"crossref","first-page":"E1025","DOI":"10.1210\/jc.2010-3023","article-title":"Prevalence and incidence of diabetes mellitus in GH-treated children and adolescents: analysis from the GeNeSIS observational research program","volume":"96","author":"Child","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071622483907800_B15","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.2337\/dc16-S005","article-title":"2. Classification and diagnosis of diabetes","volume":"39","author":"American Diabetes Association","year":"2016","journal-title":"Diabetes Care"},{"key":"2020071622483907800_B16","unstructured":"Centers for Disease Control and Prevention. CDC Wonder Database. Available at: www.wonder.cdc.gov. Accessed 29 July 2016."},{"key":"2020071622483907800_B17","unstructured":"World Health Organization. Global Health Observatory data repository. Available at: www.who.int\/ghodata. Accessed 29 July 2016."},{"key":"2020071622483907800_B18","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.2337\/dc09-S202","article-title":"Diabetes in non-Hispanic white youth: prevalence, incidence, and clinical characteristics: the SEARCH for Diabetes in Youth Study","volume":"32","author":"Bell","year":"2009","journal-title":"Diabetes Care"},{"key":"2020071622483907800_B19","unstructured":"Surveillance, Epidemiology, and End Results Program, National Cancer Institute, National Institutes of Health, US Department of Health and Human Services. SEER*Stat Database: Incidence\u2014SEER 14 Regs Research Data, Nov 2014 Sub (1992-2012) (Katrina\/Rita Population Adjustment). Available at: www.seer.cancer.gov\/data\/seerstat\/nov2014. Accessed 21 January 2016."},{"key":"2020071622483907800_B20","volume-title":"GLOBOCAN 2012 v1.0.Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11","author":"Ferlay","year":"2013"},{"issue":"82","key":"2020071622483907800_B21","first-page":"1","article-title":"Statistical methods in cancer research, volume II: the design and analysis of cohort studies","volume":"82","author":"Breslow","year":"1987","journal-title":"IARC Sci Publ"},{"issue":"4","key":"2020071622483907800_B22","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1530\/EJE-12-0967","article-title":"Incidence of second neoplasm in childhood cancer survivors treated with GH: an analysis of GeNeSIS and HypoCCS","volume":"168","author":"Woodmansee","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2020071622483907800_B23","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1530\/EJE-15-1017","article-title":"Is safety of childhood growth hormone therapy related to dose? Data from a large observational study","volume":"174","author":"S\u00e4vendahl","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2020071622483907800_B24","doi-asserted-by":"crossref","first-page":"E213","DOI":"10.1210\/jc.2011-2882","article-title":"Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study","volume":"97","author":"S\u00e4vendahl","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2020071622483907800_B25","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1210\/jc.2015-3951","article-title":"Mortality is not increased in recombinant human growth hormone\u2012treated patients when adjusting for birth characteristics","volume":"101","author":"Albertsson-Wikland","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2020071622483907800_B26","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/cen.13502","article-title":"Long-term safety of growth hormone: a combined registry analysis","volume":"88","author":"Stochholm","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"15","key":"2020071622483907800_B27","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1001\/archinternmed.2009.209","article-title":"Diabetes mellitus in long-term survivors of childhood cancer: increased risk associated with radiation therapy: a report for the childhood cancer survivor study","volume":"169","author":"Meacham","year":"2009","journal-title":"Arch Intern Med"},{"issue":"4","key":"2020071622483907800_B28","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1210\/jc.2016-3145","article-title":"Risk of diabetes treated in early adulthood after growth hormone treatment of short stature in childhood","volume":"102","author":"Poidvin","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2020071622483907800_B29","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000448841","article-title":"The influence of growth hormone treatment on glucose homeostasis in growthhormone-deficient children: a six-year follow-up study","volume":"86","author":"Baronio","year":"2016","journal-title":"Horm Res Paediatr"},{"issue":"2","key":"2020071622483907800_B30","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpeds.2010.02.028","article-title":"Growth hormone treatment in children is not associated with an increase in the incidence of cancer: experience from KIGS (Pfizer International Growth Database)","volume":"157","author":"Wilton","year":"2010","journal-title":"J Pediatr"},{"issue":"5","key":"2020071622483907800_B31","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1210\/jc.2016-2046","article-title":"Cancer risks in patients treated with growth hormone in childhood: the SAGhE European Cohort Study","volume":"102","author":"Swerdlow","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"9329","key":"2020071622483907800_B32","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0140-6736(02)09519-3","article-title":"Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study","volume":"360","author":"Swerdlow","year":"2002","journal-title":"Lancet"},{"key":"2020071622483907800_B33","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3389\/fendo.2011.00081","article-title":"Long term sequelae of pediatric craniopharyngioma: literature review and 20 years of experience","volume":"2","author":"Cohen","year":"2011","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2020071622483907800_B34","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1200\/JCO.2001.19.2.480","article-title":"Growth hormone replacement therapy in children with medulloblastoma: use and effect on tumor control","volume":"19","author":"Packer","year":"2001","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020071622483907800_B35","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0022-3476(96)70002-1","article-title":"Brain tumor recurrence in children treated with growth hormone: the National Cooperative Growth Study experience","volume":"128","author":"Moshang","year":"1996","journal-title":"J Pediatr"},{"issue":"10","key":"2020071622483907800_B36","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1080\/08035250600577889","article-title":"Recurrence of brain tumours in patients treated with growth hormone: analysis of KIGS (Pfizer International Growth Database)","volume":"95","author":"Darendeliler","year":"2006","journal-title":"Acta Paediatr"},{"issue":"12","key":"2020071622483907800_B37","first-page":"4444","article-title":"Growth hormone treatment of children with brain tumors and risk of tumor recurrence","volume":"85","author":"Swerdlow","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2020071622483907800_B38","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/j.jocn.2014.04.016","article-title":"Growth hormone treatment and risk of recurrence or development of secondary neoplasms in survivors of pediatric brain tumors","volume":"21","author":"Wang","year":"2014","journal-title":"J Clin Neurosci"},{"issue":"10","key":"2020071622483907800_B39","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s10072-015-2269-z","article-title":"Growth hormone therapy and risk of recurrence\/progression in intracranial tumors: a meta-analysis","volume":"36","author":"Shen","year":"2015","journal-title":"Neurol Sci"},{"issue":"6","key":"2020071622483907800_B40","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1210\/jc.2013-4159","article-title":"Growth hormone exposure as a risk factor for the development of subsequent neoplasms of the central nervous system: a report from the Childhood Cancer Survivor Study","volume":"99","author":"Patterson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2020071622483907800_B41","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s11102-013-0529-6","article-title":"Adult mortality or morbidity is not increased in childhood-onset growth hormone deficient patients who received pediatric GH treatment: an analysis of the Hypopituitary Control and Complications Study (HypoCCS)","volume":"17","author":"Mo","year":"2014","journal-title":"Pituitary"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/104\/2\/379\/27201994\/jc.2018-01189.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/104\/2\/379\/27201994\/jc.2018-01189.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T11:16:35Z","timestamp":1594984595000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/104\/2\/379\/5095447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,13]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2018-01189","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,2]]},"published":{"date-parts":[[2018,9,13]]}}}